Mark Rubin, MD
Director, Englander Institute for Precision Medicine of Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY
Homer T. Hirst Professor of Oncology in Pathology Vice Chair of Molecular and Genomic Pathology of Weill Cornell Medicine, New York, NY
Associate Director for Precision Medicine, Meyer Cancer Center of Weill Cornell Medicine, New York, NY
Dr. Rubin is a recognized as a world leader in the area of prostate cancer genomics and pathology. He is a board-certified pathologist with expertise in prostate cancer pathology and the translation of novel findings to clinical investigations. As a laboratory-based researcher, Dr. Rubin has more than 15 years experience in biomarker discovery and characterization. He is currently Co-PI with Dr. Arul M. Chinnaiyan (University of Michigan) of a Biomarker Discovery Laboratory of the EDRN, and works closely with Dr. Levi Garraway (Broad Institute) on whole genome and exome sequencing of prostate cancer.
In his role as a scientific leader at Weill Cornell Medicine, he is the Founding Director of the recently established Englander Institute for Precision Medicine. He is primarily responsible for its scientific development and oversight for all genomics, computational cancer genomics, and biobanking activities related to the diagnosis and treatment of cancers. Among his seminal observations in prostate cancer genomics and biomarker development, Dr. Rubin was the co-Senior Investigator of the first gene expression profiling study in prostate cancer (Nature, 2001) and the first whole genome and exome DNA sequencing studies in prostate cancer (Nature, 2011 and Nature Genetics, 2012). This work led to the discovery and development of several prostate cancer biomarkers, including AMACR, Hepsin, Pim1, EZH2, JAGGED1, SPOP, MED12, MYCN, and AURKA. Working with Dr. Chinnaiyan, he played a pivotal role in the landmark discovery of recurrent ETS rearrangements in prostate cancer, most often involving TMPRSS2:ERG (Science, 2005). Their recent genomics work has defined an SPOP mutant subclass of prostate cancer, as defined by a high susceptibility to double stranded DNA damage (Cell, 2013). Additionally, their discovery of AURKA/MYCN amplified aggressive prostate cancer (Cancer Discovery, 2013) has led to a Phase II Trial of MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine PCa (NCT01799278).